<div id="readability-page-1"><p>Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer today and set a price target of $28.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Flynn is a 4-star analyst with an average return of <span>9.2%</span> and a 58.23% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Eli Lilly &amp; Co, Bristol-Myers Squibb, and Gilead Sciences.</p> <p>In addition to Morgan Stanley, Pfizer also received a Hold from J.P. Morgan’s Chris Schott in a report issued on December 10. However, on the same day, HSBC maintained a Buy rating on Pfizer (NYSE: PFE).</p></div>

<p>Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer with a $28.00 price target. Flynn, a 4-star analyst, has a 9.2% average return and a 58.23% success rate. J.P. Morgan also rated Pfizer as Hold, while HSBC maintained a Buy rating. Flynn covers the Healthcare sector, including Eli Lilly & Co, Bristol-Myers Squibb, and Gilead Sciences.</p>

- Morgan Stanley analyst Terence Flynn has maintained a Hold rating on Pfizer with a price target of $28.00.  
- Flynn, a 4-star analyst, has an average return of 9.2% and a 58.23% success rate, covering the Healthcare sector.  
- J.P. Morgan also issued a Hold rating on Pfizer, while HSBC maintained a Buy rating on the same day.  

Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE)